Literature DB >> 20686426

Impact of clinical pathway on quality of care in sickle cell patients.

Archana Jayaram1, Rollin W Nagel, Rama Jasty.   

Abstract

Clinical pathways are disease specific and are designed to standardize care. They are intended to serve the purpose of improving quality of care and decreasing healthcare and societal costs. A retrospective cross-sectional study was conducted comparing sickle cell patients admitted to Mercy Children's Hospital (MCH) from June 1999 to November 2001 before the implementation of the clinical care pathway (n=66), to a similar group of patients admitted from December 2001 to July 2004 after pathway (n=121) implementation. The χ2 tests were used to compare categoric variables and independent t-tests for continuous variables. The results indicate improvement in compliance postpathway with specific care elements: incentive spirometry, pulse oximetry, ordering comfort measures, right dosage of pain medications, and achieving excellent nursing compliance in documenting pain scores. There was a significant decrease in the number of blood transfusions in postpathway patients. Though limited by sample size, the results suggest that clinical pathways are good tools for standardization of care in certain care elements and help to improve quality of care in sickle cell patients.

Entities:  

Mesh:

Year:  2010        PMID: 20686426     DOI: 10.1097/MPH.0b013e3181e7570a

Source DB:  PubMed          Journal:  J Pediatr Hematol Oncol        ISSN: 1077-4114            Impact factor:   1.289


  2 in total

1.  Clinical Pathway for Vaso-Occlusive Pain Reduces Hospital Admissions.

Authors:  Wallace Jones; Albert Jang; Leann Myers; Aditi Dasgupta; Jessica DeBord
Journal:  J Healthc Qual       Date:  2022 Jan-Feb 01       Impact factor: 1.095

2.  A nurse-initiated jaundice management protocol improves quality of care in the paediatric emergency department.

Authors:  Michelle Long; Ken J Farion; Roger Zemek; Debby Voskamp; Nick Barrowman; Salwa Akiki; Sarah Reid
Journal:  Paediatr Child Health       Date:  2017-06-22       Impact factor: 2.253

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.